chufangao/CTO huggingface dataset:
Clinical trial NCT03845517: A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Official title: A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06700841 IN PARTICIPANTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 350.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-04-18
Primary completion date: 2023-10-05
Completion date: 2023-10-05
Baseline population: Safety analysis set included all participants who were randomly assigned to study intervention and who took at least 1 dose of study intervention.
Limitations and caveats: For the PF-06700841 30 mg, there was a total of 1 death which was reported in both on-treatment and follow-up phases in participant flow section.
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT04855565: ALY688-SR in Generally Healthy Overweight or Obese Adults
Official title: Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Subcutaneous Doses of ALY688-SR in Generally Healthy Overweight or Obese Adults
Sponsor: Allysta Pharmaceutical (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Inability to recruit due to COVID-19 pandemic restrictions
Enrollment: 8.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-05-19
Primary completion date: 2021-08-03
Completion date: 2021-08-03
Plan to share individual participant data: NO
Clinical trial NCT04347226: Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19
Official title: A Randomized Phase 2 Study of Anti-IL-8 Therapy Versus Standard of Care in the Treatment of Hospitalized Patients With Severe COVID-19
Sponsor: Columbia University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Interim analysis indicated that futility boundary was reached.
Enrollment: 43.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-04-16
Primary completion date: 2021-03-01
Completion date: 2021-03-01
Clinical trial NCT02961816: Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma
Official title: Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Lack of funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-06-30
Primary completion date: 2021-06-30
Completion date: 2021-06-30
Clinical trial NCT03839355: Trial of Apixaban vs Warfarin in Reducing Rate of Cognitive Decline, Silent Cerebral Infarcts and Cerebral Microbleeds in Patients With Atrial Fibrillation
Official title: Randomized Trial of Apixaban vs Dose Adjusted Warfarin in Reducing Rate of Cognitive Function Decline, Silent Cerebral Infarcts and Cerebral Microbleeds in Non-valvular Atrial Fibrillation Patients With CHA2DS2-VaSc Score = 2
Acronym: ARISTA
Sponsor: Mayo Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Study terminated due to slower than anticipated enrollment.
Enrollment: 34.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-12-19
Primary completion date: 2020-12-15
Completion date: 2020-12-15
Clinical trial NCT04006652: ApoGraft for the Prevention of Acute Graft Versus Host Disease in Haploidentical Hematopoietic Cell Transplant Recipients
Official title: A Phase I Study of ApoGraft for the Prevention of Acute Graft Versus Host Disease in Haploidentical Hematopoietic Cell Transplant Recipients
Sponsor: Washington University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Lost funding
Enrollment: 4.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-12-16
Primary completion date: 2022-12-19
Completion date: 2022-12-19
Plan to share individual participant data: NO
Clinical trial NCT03241745: A Study of Nivolumab in Selected Uterine Cancer Patients
Official title: Phase II Trial of Single-Agent Nivolumab in Patients With Microsatellite Unstable/Mismatch Repair Deficient/Hypermutated Uterine Cancer
Sponsor: Memorial Sloan Kettering Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 35.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-08-03
Primary completion date: 2024-04-01
Completion date: 2024-04-01
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03711162: A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care
Official title: A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Two Doses of GLPG1690 in Addition to Local Standard of Care for Minimum 52 Weeks in Subjects With Idiopathic Pulmonary Fibrosis
Acronym: ISABELA1
Sponsor: Galapagos NV (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: The benefit-risk profile no longer supports continuing the study
Enrollment: 525.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-11-28
Primary completion date: 2021-03-30
Completion date: 2021-03-30
Baseline population: Full analysis set (FAS) consisted of all randomized participants who received at least 1 dose of investigational product (IP).
Limitations and caveats: This Study was prematurely terminated based on recommendations of the Independent Data Monitoring Committee.
Plan to share individual participant data: NO
Clinical trial NCT05110651: The Danish Pre-HCQ COVID Dialysis Study
Official title: The Danish Pre-HCQ Dialysis Study: Hydroxychloroquine for Prevention of COVID19 in Dialysis-treated Patients With End-stage Renal Disease - A Multicenter Parallel-group Open Randomized Clinical Trial
Sponsor: Rigshospitalet, Denmark (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: No funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-04-10
Primary completion date: 2020-07-31
Completion date: 2020-10-01
Plan to share individual participant data: YES
IPD sharing description: Aggregated de-identified individual participant data for primary and secondary outcomes measures will be made available
IPD time frame: Aggregated data will be available within 12 months of study completion
IPD access criteria: All data access requests via email. Requestors will be required to sign a Data Access Agreement
Clinical trial NCT05788458: Effect of Bupivacaine Concentration on Ultrasound Guided Pericapsular Group Nerve Block Efficacy in Hip Surgery Patients
Official title: Effect of Bupivacaine Concentration on Ultrasound Guided Pericapsular Group Nerve Block Efficacy in Hip Surgery Patients: A Randomized Controlled Double Blinded Trial
Sponsor: Benha University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 135.0 (ACTUAL)
Number of arms: 3.0
Start date: 2023-04-01
Primary completion date: 2023-10-01
Completion date: 2023-11-01
Clinical trial NCT03855137: Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine
Official title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine (Progress)
Sponsor: Allergan (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 778.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-03-11
Primary completion date: 2022-01-20
Completion date: 2022-01-20
Baseline population: Intent-to-treat (ITT) population included all randomized participants.
Plan to share individual participant data: YES
IPD sharing description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
IPD time frame: For details on when studies are available for sharing visit, please refer to the link below.
IPD access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.
Clinical trial NCT04810104: Parkinson's Disease With Mild Cognitive Impairment Treated With Nicotinic Agonist Drug
Official title: Parkinson's Disease With Mild Cognitive Impairment Treated With Nicotinic Agonist Drug
Acronym: PD-MIND
Sponsor: King's College London (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Delays due to COVID
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-10-31
Primary completion date: 2024-01-31
Completion date: 2024-04-30
Plan to share individual participant data: NO
Clinical trial NCT04556617: PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Official title: A Multicenter, Open-Label, Parallel, Phase 1b/2a Study of PLX2853 in Combination With Abiraterone Acetate and Prednisone and Phase 1b/2a Study of PLX2853 in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Sponsor: Opna Bio LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: study terminated due to business realignment
Enrollment: 19.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-21
Primary completion date: 2022-05-24
Completion date: 2022-05-24
Clinical trial NCT05522673: [11C]-(R)-Rolipram to Measure cAMP Signaling Before and After Ketamine
Official title: [11C]-(R)-Rolipram to Measure cAMP Signaling Before and After Ketamine
Sponsor: National Institutes of Health Clinical Center (CC) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Low recruitment
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2023-02-08
Primary completion date: 2023-02-08
Completion date: 2024-01-30
Limitations and caveats: Study was prematurely terminated due to low recruitment
Plan to share individual participant data: NO
Clinical trial NCT03800602: Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer
Official title: Phase II Trial of Nivolumab and Metformin in Patients With Treatment Refractory MSS Metastatic Colorectal Cancer
Sponsor: Emory University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 29.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-01-15
Primary completion date: 2020-09-04
Completion date: 2021-09-04
Clinical trial NCT04609579: Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma
Official title: A Phase 1 Open-label Study of SNX281 Given as Monotherapy and in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors and Lymphoma
Sponsor: Stingthera, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Sponsor decision (not due to safety concerns)
Enrollment: 27.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-11-18
Primary completion date: 2024-01-06
Completion date: 2024-01-06
Plan to share individual participant data: NO
Clinical trial NCT02128763: Dry Eye Assessment and Management Study
Official title: Dry Eye Assessment and Management Study
Acronym: DREAM
Sponsor: University of Pennsylvania (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 535.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-11-30
Primary completion date: 2017-09-05
Completion date: 2020-01-31
Clinical trial NCT05261711: AB1 in Adult Patients With Sickle Cell Disease (SCD)
Official title: A Phase 1/2, Open-Label, Dose Escalating Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AB1 in Adult Patients With Sickle Cell Disease (SCD)
Acronym: (SCD)
Sponsor: Duke University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: SUSPENDED 
Why stopped: Study is currently on hold pending a protocol amendment to change the dosing.
Enrollment: 39.0 (ESTIMATED)
Number of arms: 1.0
Start date: 2022-12-05
Primary completion date: 2024-11-30
Completion date: 2024-11-30
Plan to share individual participant data: NO
Clinical trial NCT04362111: Early Treatment of Cytokine Storm Syndrome in Covid-19
Official title: Early Treatment of Cytokine Storm Syndrome in Covid-19
Sponsor: University of Alabama at Birmingham (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 32.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-08-01
Primary completion date: 2021-12-31
Completion date: 2023-06-01
Limitations and caveats: 1. All subjects received daily dexamethasone to the standard of care management of Covid-19 pneumonia requiring hospitalization.~2. Some of the enrolled subjects with rapid improvement were discharged prior to 10 days with instructions on anakinra self-administration at home; adherence with unsupervised dosing of study agent could not be readily assessed, nor could reported oxygen saturations be confirmed in these participants.
Plan to share individual participant data: YES
IPD sharing description: Contact PI by e-mail for protocol specifics Submission of results for peer reviewed publication
IPD time frame: During study enrollment
IPD access criteria: wchatham@uabmc.edu
Clinical trial NCT04267393: Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH)
Official title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Dose Phase 2 Study to Evaluate the Efficacy and Safety of BMS-986263 in Adults With Compensated Cirrhosis From Nonalcoholic Steatohepatitis (NASH)
Sponsor: Bristol-Myers Squibb (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Trial terminated because of lack of efficacy in the short term acute phase.
Enrollment: 124.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-03-17
Primary completion date: 2023-08-16
Completion date: 2024-02-09
Baseline population: All Randomized Participants
Clinical trial NCT03720717: Baclofen as a Perioperative Analgesic Adjuvant
Official title: Baclofen as a Perioperative Analgesic Adjuvant
Sponsor: University of Alabama at Birmingham (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Futility analysis at midpoint analysis
Enrollment: 34.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-10-27
Primary completion date: 2022-10-28
Completion date: 2022-10-28
Plan to share individual participant data: YES
IPD sharing description: De-identified individual data available on reasonable request - currently in RedCap system
IPD time frame: Published - Cureus 2024 - DOI: 10.7759/cureus
IPD access criteria: published
Clinical trial NCT04150250: Cholera Anti-Secretory Treatment Trial
Official title: A Phase 2a Randomized, Single-Center, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Preliminary Efficacy of Oral iOWH032 Against Cholera Diarrhea in a Controlled Human Infection Model
Acronym: CAST
Sponsor: PATH (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 47.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-11-04
Primary completion date: 2020-07-27
Completion date: 2020-07-27
Baseline population: All enrolled participants
Plan to share individual participant data: NO
Clinical trial NCT05157464: Losartan Use to Mitigate Arthrofibrosis Following Total Join Arthroplasty
Official title: Losartan Use to Mitigate Arthrofibrosis Following Total Join Arthroplasty
Sponsor: NYU Langone Health (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Study was not initiated, no participants enrolled.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-09-01
Primary completion date: 2024-12-31
Completion date: 2024-12-31
Plan to share individual participant data: YES
IPD sharing description: Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices) will be available upon reasonable request.
IPD time frame: Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.
IPD access criteria: The investigator who proposed to use the data will have access upon reasonable request. Requests should be directed to daniel.waren@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.
Clinical trial NCT01842399: Resveratrol and Cardiovascular Health in the Elderly
Official title: Resveratrol and Cardiovascular Health in the Elderly: The Reache Trial
Sponsor: National Institutes of Health Clinical Center (CC) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: The protocol experienced slow accrual.
Enrollment: 73.0 (ACTUAL)
Number of arms: 3.0
Start date: 2015-07-14
Primary completion date: 2020-07-31
Completion date: 2022-12-21
Plan to share individual participant data: UNDECIDED
IPD sharing description: .There is ongoing discussion within the NIA IRP and a plan has not been finalized yet.
Clinical trial NCT05402995: Randomized Trial Comparing Irrisept to Saline Irrigation for Infection Prevention
Official title: Prospective Randomized Control Trial Comparing Irrisept to Saline Irrigation for the Prevention of Infection After Open Tibia Fractures
Sponsor: University of Missouri-Columbia (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Enrollment was not progressing as expected.
Enrollment: 6.0 (ACTUAL)
Number of arms: 4.0
Start date: 2022-06-21
Primary completion date: 2023-08-31
Completion date: 2023-08-31
Baseline population: As study was terminated due to difficulty enrolling participants there was no one randomized to the reference/control group.
Plan to share individual participant data: NO
Clinical trial NCT03557307: Study to Evaluate Efficacy and Safety of Benralizumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma
Official title: PONENTE: A Multicenter, Open-label, Phase 3b Efficacy and Safety Study of Benralizumab 30 mg Administered Subcutaneously to Reduce Oral Corticosteroid Use in Adult Patients With Severe Eosinophilic Asthma on High Dose Inhaled Corticosteroid Plus Long-acting β2 Agonist and Chronic Oral Corticosteroid Therapy
Acronym: PONENTE
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 598.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-08-01
Primary completion date: 2021-04-16
Completion date: 2022-03-24
Baseline population: Full analysis set
Limitations and caveats: During COVID-19 pandemic, for ongoing patients, patient dosing, and scheduled visits are inevitably impacted, but the primary endpoint was not impacted.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Clinical trial NCT05453942: A Study to Investigate Safety, Tolerability and Clinical Response With SAR441566 Compared With Placebo in Participants With Mild to Moderate Psoriasis
Official title: A Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability and Clinical Response After 4-week Oral Treatment With SAR441566 Compared With Placebo in Participants With Mild to Moderate Psoriasis
Sponsor: Sanofi (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 38.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-07-12
Primary completion date: 2023-02-09
Completion date: 2023-02-09
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Clinical trial NCT02576717: A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
Official title: A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Sponsor: Celgene (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 2494.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-10-16
Primary completion date: 2023-01-05
Completion date: 2023-01-05
Baseline population: Demographics were summarized using the safety population - all participants enrolled in study RPC01-3001 who received at least one dose of open-label RPC1063.
Clinical trial NCT03554200: EMPA Acute Heart Failure
Official title: Effect of Empagliflozin on Cardiac Output in Patients With Acute Heart Failure (EMPA Acute Heart Failure)
Sponsor: RWTH Aachen University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: COVID 19
Enrollment: 19.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-06-11
Primary completion date: 2020-10-29
Completion date: 2020-10-29
Plan to share individual participant data: NO
Clinical trial NCT03408652: Efficacy and Safety of Systemic Treatments of Bone Metastases From Kidney Cancer in Patients Treated With Targeted Therapies
Official title: Multicenter Randomized Phase III Study Evaluating the Efficacy and Safety of Systemic Treatments of Bone Metastases From Kidney Cancer in Patients Treated With Targeted Therapies
Acronym: MOSCAR
Sponsor: Centre Leon Berard (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: lack of recruitment
Enrollment: 1.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-03-15
Primary completion date: 2020-06-22
Completion date: 2020-06-22